Table 2.

Factors associated with imminent risk of fracture in 12- and 24-month follow-ups

Factors	12-month risk		24-month risk
	Hazard ratio	95% CI	Hazard ratio	95% CI
Demographic
Age in years
67–69	Reference		Reference
70–74	1.22	1.17–1.26	1.22	1.19–1.26
75–79	1.69	1.63–1.76	1.73	1.68–1.77
80–84	2.29	2.21–2.37	2.38	2.32–2.44
85+	3.12	3.01–3.23	3.27	3.19–3.35
Male	0.55	0.54–0.56	0.54	0.53–0.55
Race
While	Reference
Black	0.43	0.41–0.45	0.42	0.41–0.44
Hispanic	0.70	0.66–0.75	0.72	0.69–0.75
Asian	0.66	0.62–0.71	0.66	0.63–0.69
Other	0.81	0.75–0.87	0.80	0.76—0.85
History of Fracture	2.46	2.41–2.52	2.21	2.17–2.25
History of Falls	1.18	1.14–1.21	1.16	1.14–1.19
Clinical conditions
Osteoporosis	1.22	1.18–1.25	1.21	1.18–1.24
Cardiovascular disease	1.11	1.09–1.13	1.12	1.10–1.13
COPD	1.16	1.14–1.19	1.17	1.15–1.19
Ankylosing spondylitis	1.52	1.36–1.70	1.41	1.29–1.55
Depression	1.14	1.11–1.17	1.13	1.11–1.16
Mood or anxiety orders	1.07	1.03–1.11	1.10	1.07–1.13
Frailty markers
Ambulance/life support	1.16	1.13–1.19	1.15	1.13–1.17
Difficulty walking	1.15	1.12–1.18	1.14	1.12–1.16
Use of DME	1.12	1.09–1.14	1.11	1.09–1.13
Concomitant medications
Osteoporosis medicationsa	1.26	1.24–1.29	1.27	1.25–1.29
Glucocorticoids	1.13	1.11–1.15	1.13	1.12–1.15
Heparin	1.21	1.14–1.28	1.16	1.11–1.21
CNS active medicationsa	1.13	1.10–1.16	1.11	1.09–1.13

CNS central nervous system, COPD chronic obstructive pulmonary disease, DME durable medical equipment

^aOsteoporosis medications include bisphosphonates, calcitonin, teriparatide, raloxifene, denosumab. CNS active medications include tricyclic antidepressants, monoamine oxidase inhibitors, antipsychotic agents, lithium